HC Wainwright Reaffirms "Buy" Rating for Sana Biotechnology (NASDAQ:SANA)

Sana Biotechnology (NASDAQ:SANA - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright's price target would indicate a potential upside of 180.70% from the company's previous close.

A number of other research firms also recently weighed in on SANA. JMP Securities downgraded shares of Sana Biotechnology from an "outperform" rating to a "market perform" rating in a report on Tuesday, November 5th. Citigroup raised their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, August 9th.

Sana Biotechnology Stock Down 5.3 %

SANA traded down $0.16 during trading on Monday, reaching $2.85. The stock had a trading volume of 1,406,121 shares, compared to its average volume of 2,148,165. Sana Biotechnology has a 1-year low of $2.76 and a 1-year high of $12.00. The firm has a market capitalization of $634.03 million, a price-to-earnings ratio of -2.29 and a beta of 1.44. The stock has a 50 day moving average of $4.21 and a two-hundred day moving average of $5.77.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.04). On average, research analysts forecast that Sana Biotechnology will post -1.13 EPS for the current fiscal year.

Insider Buying and Selling at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of the company's stock in a transaction on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the transaction, the director now directly owns 2,848,121 shares in the company, valued at $11,620,333.68. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 31.10% of the company's stock.

Institutional Investors Weigh In On Sana Biotechnology

A number of institutional investors have recently bought and sold shares of SANA. Blue Trust Inc. lifted its holdings in shares of Sana Biotechnology by 1,246.6% during the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company's stock worth $55,000 after acquiring an additional 12,154 shares during the period. Cornercap Investment Counsel Inc. acquired a new position in shares of Sana Biotechnology in the 3rd quarter worth approximately $67,000. Algert Global LLC bought a new position in shares of Sana Biotechnology during the 2nd quarter worth approximately $73,000. XTX Topco Ltd acquired a new stake in shares of Sana Biotechnology in the 2nd quarter valued at $100,000. Finally, Dark Forest Capital Management LP increased its holdings in shares of Sana Biotechnology by 112.0% during the second quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company's stock worth $149,000 after buying an additional 14,430 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.